TY - JOUR
T1 - Annual mammographic screening to reduce breast cancer mortality in women from age 40 years
T2 - long-term follow-up of the UK Age RCT
AU - Duffy, Stephen
AU - Vulkan, Daniel
AU - Cuckle, Howard
AU - Parmar, Dharmishta
AU - Sheikh, Shama
AU - Smith, Robert
AU - Evans, Andrew
AU - Blyuss, Oleg
AU - Johns, Louise
AU - Ellis, Ian
AU - Sasieni, Peter
AU - Wale, Chris
AU - Myles, Jonathan
AU - Moss, Sue
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Background There remains disagreement on the long-term effect of mammographic screening in women aged 40-49 years. Objectives The long-term follow-up of a randomised controlled trial that offered annual mammography to women aged 40-49 years. The estimation of the effect of these mammograms on breast cancer and other-cause mortality, and the effect on incidence, with implications for overdiagnosis. Design An individually randomised controlled trial comparing offering annual mammography with offering usual care in those aged 40-48 years, and thus evaluating the effect of annual screening entirely taking place before the age of 50 years. There was follow-up for an average of 23 years for breast cancer incidence, breast cancer death and death from other causes. We analysed the mortality and incidence data by Poisson regression and estimated overdiagnosis formally using Markov process models. Set ting Twenty-three screening units in England, Wales and Scotland within the NHS Breast Screening Programme. Participants Women aged 39-41 years were recruited bet ween 1990 and 1997. After exclusions, a total of 53,883 women were randomised to undergo screening (the intervention group) and 106,953 women were randomised to have usual care (the control group). Interventions The intervention group was invited to an annual breast screen with film mammography, two view at first screen and single view thereafter, up to and including the calendar year of their 48th birthday. The control group received no intervention. Both groups were invited to the National Programme from the age of 50 years, when screening is offered to all women in the UK. Main outcome measures The main outcome measures were mortality from breast cancers diagnosed during the intervention phase of the trial (i.e. before the first National Programme screen at 50 years), mortality from all breast cancers diagnosed after randomisation, all-cause mortality, mortality from causes other than breast cancer, and the incidence of breast cancer.
AB - Background There remains disagreement on the long-term effect of mammographic screening in women aged 40-49 years. Objectives The long-term follow-up of a randomised controlled trial that offered annual mammography to women aged 40-49 years. The estimation of the effect of these mammograms on breast cancer and other-cause mortality, and the effect on incidence, with implications for overdiagnosis. Design An individually randomised controlled trial comparing offering annual mammography with offering usual care in those aged 40-48 years, and thus evaluating the effect of annual screening entirely taking place before the age of 50 years. There was follow-up for an average of 23 years for breast cancer incidence, breast cancer death and death from other causes. We analysed the mortality and incidence data by Poisson regression and estimated overdiagnosis formally using Markov process models. Set ting Twenty-three screening units in England, Wales and Scotland within the NHS Breast Screening Programme. Participants Women aged 39-41 years were recruited bet ween 1990 and 1997. After exclusions, a total of 53,883 women were randomised to undergo screening (the intervention group) and 106,953 women were randomised to have usual care (the control group). Interventions The intervention group was invited to an annual breast screen with film mammography, two view at first screen and single view thereafter, up to and including the calendar year of their 48th birthday. The control group received no intervention. Both groups were invited to the National Programme from the age of 50 years, when screening is offered to all women in the UK. Main outcome measures The main outcome measures were mortality from breast cancers diagnosed during the intervention phase of the trial (i.e. before the first National Programme screen at 50 years), mortality from all breast cancers diagnosed after randomisation, all-cause mortality, mortality from causes other than breast cancer, and the incidence of breast cancer.
KW - AGE
KW - BREAST CANCER
KW - MAMMOGRAPHY
KW - SCREENING
UR - http://www.scopus.com/inward/record.url?scp=85095615632&partnerID=8YFLogxK
U2 - 10.3310/hta24550
DO - 10.3310/hta24550
M3 - Article
C2 - 33141657
AN - SCOPUS:85095615632
SN - 1366-5278
VL - 24
SP - 1
EP - 24
JO - Health technology assessment (Winchester, England)
JF - Health technology assessment (Winchester, England)
IS - 55
ER -